DEF 14A: Jaguar Health Seeks Stockholder Approval for Reverse Stock Split, Share Issuance, and Meeting Adjournment

Jaguar Health is holding a special meeting to seek stockholder approval for a reverse stock split, the issuance of common stock upon exchange of preferred stock, the issuance of shares to accredited investors, and the potential adjournment of the meeting to solicit additional proxies.

Summary

• Jaguar Health, Inc. is convening a Special Meeting of Stockholders on April 9, 2024, to vote on four proposals.
• Proposal 1 involves approving an amendment to the company's Third Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-150, with the exact ratio to be determined by the Board of Directors within one year of approval.
• Proposal 2 seeks approval for the issuance of Common Stock upon exchange of Series J Perpetual Preferred Stock to certain accredited investors, in accordance with Nasdaq Listing Rule 5635(d).
• Proposal 3 asks for approval, under Rule 5635(d), for the issuance of 18,837,500 shares of Common Stock to certain accredited investors through exchange agreements dated February 27, 2024.
• Proposal 4 concerns the approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if sufficient votes are not present to approve the first three proposals.
• The Board of Directors recommends voting FOR all four proposals.

Sentiment

Score: 5

Explanation: The document is primarily procedural, outlining proposals for stockholder vote. While the reverse stock split and share issuance suggest financial challenges, the overall tone is neutral and focused on compliance.

Positives

• The reverse stock split aims to increase the price of the Common Stock to meet Nasdaq's minimum bid price requirement.
• The company believes the reverse stock split could reduce certain costs, such as Nasdaq listing fees.
• A higher stock price may attract a broader range of institutional and other investors, potentially improving trading liquidity.
• The exchange of royalty interest for Series J Preferred Stock eliminated the outstanding balance of the March 2021 Royalty Interest.
• Approval of Proposal 3 would prevent the aggregation of the issuance of 18,837,500 shares of Common Stock with future private placements for Nasdaq Listing Rule 5635(d) purposes.

Negatives

• Reverse stock splits can have a negative perception among some investors.
• The stock price of companies that have effected reverse stock splits has sometimes declined back to pre-split levels.
• There is no guarantee that the market price of the Common Stock will increase following the reverse stock split.
• The issuance of Common Stock upon exchange of the Series J Preferred Stock will have a dilutive effect on current stockholders.
• If the reverse stock split is not approved, the company's ability to remain listed on The Nasdaq Capital Market would be significantly and negatively affected.

Risks

• The market price of the Common Stock may fluctuate and potentially decline after the Reverse Stock Split.
• The resulting per-share market price may not attract institutional investors or investment funds.
• The Board of Directors' ability to issue authorized and unissued shares without further stockholder action will increase.
• If the Common Stock is delisted, it may adversely affect the company's ability to obtain alternative debt or equity financing.
• The exact magnitude of the dilutive effect of any future exchange of Series J Preferred Stock cannot be conclusively determined but may be material to current stockholders.

Future Outlook

The company intends to actively monitor the trading price of its Common Stock and consider available options to resolve non-compliance with Nasdaq listing rules if the Reverse Stock Split is not approved.

Management Comments

• Lisa A. Conte, Chief Executive Officer & President, cordially invited stockholders to attend the Special Meeting.

Industry Context

The document reflects the common challenges faced by companies listed on exchanges like Nasdaq, particularly the need to maintain a minimum bid price to avoid delisting. Reverse stock splits are a relatively common mechanism employed by companies to regain compliance.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies facing delisting from exchanges like Nasdaq, similar to actions taken by other small-cap and micro-cap companies in the biotech and pharmaceutical sectors.
• The terms of the Series J Preferred Stock and the PIPE Warrant Exchange Agreements appear to be structured to comply with Nasdaq Listing Rules, a standard practice for companies seeking to maintain their listing.
• The engagement of a proxy solicitor like Georgeson LLC is a typical practice for companies seeking to ensure sufficient stockholder participation in important votes, mirroring the approach taken by many publicly traded companies.

Stakeholder Impact

• Stockholders will be impacted by the reverse stock split, potentially affecting the value and liquidity of their shares.
• The issuance of new shares will dilute existing stockholders' ownership.
• The company's ability to remain listed on Nasdaq affects its access to capital and overall financial stability, impacting all stakeholders.

Next Steps

• Stockholders need to vote on the proposals before the Special Meeting on April 9, 2024.
• The Board of Directors will determine the exact ratio for the reverse stock split, if approved, and publicly announce it.
• The company will file an amendment to the COI with the Delaware Secretary of State if the reverse stock split is approved and the Board decides to proceed.
• The company will await the decision of the Nasdaq Hearings Panel regarding an extension period to regain compliance with the minimum bid price requirement.

Key Dates

Keywords

reverse stock split, common stock, preferred stock, share issuance, Nasdaq, proxy, stockholders, Jaguar Health, accredited investors